Targeted PET/CT Imaging for Non-Small Cell Lung Cancer
In Vivo Detection of c-Met Activation Status by Specific PET/CT Imaging Based on 18F Labeled Small Molecule TKI
This study is testing a new imaging agent to see if it can help identify which patients with non-small cell lung cancer might benefit from targeted therapies based on a specific cancer marker.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 88 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Harbin Medical University Academic / other |
| Locations | 1 site (Harbin, Heilongjiang) |
| Trial ID | NCT06911697 on ClinicalTrials.gov |
What this trial studies
This study evaluates a novel imaging agent, 18F-TSPF, designed to detect c-Met activation status in patients with non-small cell lung cancer (NSCLC). Participants will undergo both 18F-TSPF PET/CT and 18F-FDG PET/CT scans to assess the specificity and accuracy of the new radiotracer. The study aims to identify which NSCLC patients may benefit from c-Met targeted therapies based on their c-Met activation status. By comparing results from different patient groups, the study seeks to enhance non-invasive diagnostic capabilities in oncology.
Who should consider this trial
Good fit: Ideal candidates include NSCLC patients aged 18-75 with confirmed c-Met activation status.
Not a fit: Patients with severe liver or renal dysfunction or those planning to conceive may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved identification of NSCLC patients who are likely to benefit from targeted c-Met therapies.
How similar studies have performed: While the approach of using targeted PET imaging is promising, this specific application of 18F-TSPF is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age range 18-75 years, open to both male and female participants; 2. Normal hepatic/renal function and cardiac function; 3. Expected survival of at least 12 weeks; 4. Good adherence to follow-up; 5. Presence of at least one measurable target lesion according to RECIST 1.1 criteria; 6. Women of childbearing age (15-49 years) must undergo a pregnancy test within seven days prior to the commencement of the study and test negative; sexually active male and female participants must agree to utilize effective contraception to prevent pregnancy during the study and for three months following the final examination; 7. Patients for whom a clinical physician recommends PET/CT scans for the diagnosis and staging of tumors; 8. Participants must fully understand and voluntarily agree to participate in the study, and must sign an informed consent form. Exclusion Criteria: 1. Severe abnormalities in liver and renal function and blood counts; 2. Patients planning to conceive; 3. Pregnant or lactating women; 4. Individuals unable to lie flat for thirty minutes; 5. Individuals who refuse to participate in this clinical study; 6. Individuals suffering from claustrophobia or other psychiatric disorders; 7. Other situations deemed unsuitable for trial participation by the researchers.
Where this trial is running
Harbin, Heilongjiang
- Department of Nuclear Medicine, Fourth Affiliated Hospital of Harbin Medical University — Harbin, Heilongjiang, China (Recruiting)
Study contacts
- Study coordinator: Xilin Sun, MD
- Email: sunxilin@aliyun.com
- Phone: +86-15904601908
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.